Italy Artificial Organs & Bionic Implants Market Size

Italy Artificial Organs & Bionic Implants Market Analysis

The Italy Artificial Organs & Bionic Implants Market is expected to register a CAGR of 2% during the forecast period.

The initial stages of the COVID-19 pandemic significantly impacted the Italy artificial organs & bionic implants market. For instance, according to an article published by the National Library of Medicine, in July 2022, during the first four weeks of the COVID-19 pandemic in Italy, there was a 25% reduction in the total organ procured. Less availability of ICU beds for both transplant recipients and donors negatively impacted total donation activity and ultimately resulted in fewer transplants. This led to a reduction in demand for artificial organs & bionic implants. However, most countries, including Italy, adopted vaccination prioritization processes, including priority for solid organ transplantation recipients to reduce the infection risk. For instance, according to the above source, transplantation rates returned to pre-pandemic levels, novel treatments were identified, and vaccination of solid organ transplantation recipients was prioritized. Approximately 80% of solid organ transplantation recipients in Italy received at least a vaccine dose by October 2021. Thus, with an increased initiative for the safety of solid organ transplantation recipients, the market started to witness a pre-pandemic level growth rate gradually.

The major factors driving the market growth are increased incidence of disabilities, organ failures and scarcity of donors, high road accidents leading to amputations, and technological advancements in artificial organs and bionics. For instance, in the article published by Istat on Road accidents in Italy, the number of accidents per 100 thousand inhabitants was higher than the national average (256.9) in 7 regions (from 473.6 in Liguria to 259.1 in Lombardy region), lower in Calabria (139.6), Molise (143.9) and Campania ( 160.7) in 2021. Thus, the high burden of road accidents in the country is expected to increase the chances of amputation, thereby fuelling the growth of the market studied over the forecast period.

Furthermore, strategic initiatives by key players such as various product development, mergers, acquisitions, and collaboration are likely to accelerate market growth. For instance, in September 2022, Pixium Vision SA announced the report of the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD), also known as Geographic Atrophy. The study was initiated in Q4 2020 in France, where the first patient was enrolled in December 2020. Pixium Vision has since established additional clinical sites and implanted patients in France, Germany, the UK, the Netherlands, and Italy. Such development is expected to drive the growth of the market in Italy over the forecast period.

However, expensive procedures and the risk of compatibility issues and malfunctions are expected to restrain the market growth.